Biotechnology in the Czech Republic where we are? Martin Bunček Technology Agency of the Czech Republic České Budějovice 20th September 2016
“great past – sad present – promising future”* •
long tradition in “classic” biotechnology
•
lagging behind in cutting-edge technologies
•
established education system, affordable and well qualified manpower
•
insufficient interaction of academia with industry, past brain drain
•
improved R&D infrastructure
•
missing tardition in spin-offs, lack of managers trained in science
•
growing awareness on IP protection in academia
•
lack of funding for patenting in academia; lack of venture capital
•
increasing R&D funding
•
growing bureaucracy; complex rules
*-presentation “Advanced Czech Biotech”, Peter Šebo, 2008
3
R&D&I Infrastructures (OP RDI & TACR CC)
Zdroj: MEY, TA CR
project support in biotech field 80
800 000
70
700 000
60
600 000
50
500 000
40
400 000
30
300 000
20
200 000
10
100 000
0
0 2007
2008
2009
2010
# projects (main area only)
2011
2012
2013 Year
# projects (suppl. area)
2014
2015
2016
subsidy (main area only)
2017
2018
2019
subsidy (main + suppl. area)
5
amount of subsidy (in thousand CZK)
# of new projects per year
(using IS VaVaI, CEP categories)
project support in biotech field (using IS VaVaI, “keyword” categories*) 80
700 000
70
60 # of new projetcs per year
500 000 50 400 000 40 300 000 30 200 000 20 100 000
10
0
0 2007
2008
2009
2010
2011
2012
2013
# projects
2014 Year
2015
2016
2017
2018
2019
2020
subsidy (thousands CZK)
6 *-keywords used for selection of projects was based on “biotech” keyword
amount of subsidy (in thousand CZK)
600 000
institutions with highest # of projects (using IS VaVaI, CEP & “keyword” categories*) CEP categories: Mikrobiologický ústav AV ČR, v. v. i. Vysoká škola chemicko-technologická v Praze / Fakulta potravinářské a biochemické technologie Výzkumný ústav rostlinné výroby, v.v.i. Ústav experimentální botaniky AV ČR, v. v. i. Fyziologický ústav AV ČR, v. v. i. Univerzita Palackého v Olomouci / Přírodovědecká fakulta Biologické centrum AV ČR, v. v. i. Ústav molekulární genetiky AV ČR, v. v. i. Masarykova univerzita / Přírodovědecká fakulta DEKONTA, a.s.
“keyword” categories: Mikrobiologický ústav AV ČR, v. v. i. Ústav experimentální botaniky AV ČR, v. v. i. Univerzita Palackého v Olomouci / Přírodovědecká fakulta DEKONTA, a.s. Univerzita Karlova v Praze / Přírodovědecká fakulta Biotechnologický ústav AV ČR, v. v. i. Vysoká škola chemicko-technologická v Praze / Fakulta potravinářské a biochemické technologie Ústav molekulární genetiky AV ČR, v. v. i. Česká zemědělská univerzita v Praze / Fakulta agrobiologie, potravinových a přírodních zdrojů Fakultní nemocnice u sv. Anny v Brně
7
“great past – sad present – promising future”* •
long tradition in “classic” biotechnology
•
lagging behind in cutting-edge technologies
•
established education system, affordable and well qualified manpower
•
insufficient interaction of academia with industry, past brain drain
•
improved R&D infrastructure
•
missing tardition in spin-offs, lack of managers trained in science
•
growing awareness on IP protection in academia
•
lack of funding for patenting in academia; lack of venture capital
•
increasing R&D funding
•
growing bureaucracy; complex rules
*-presentation “Advanced Czech Biotech”, Peter Šebo, 2008
8
“promising” future •
long tradition in “classic” biotechnology
•
lagging behind in cutting-edge technologies
•
established education system, affordable and well qualified manpower
•
insufficient interaction of academia with industry, past brain drain
•
improved R&D infrastructure
•
missing tradition in spin-offs, lack of managers trained in science
•
growing awareness on IP protection in academia
•
lack of funding for patenting in academia; lack of venture capital
•
increasing R&D funding
•
growing bureaucracy; complex rules 9
world where we live
• does even “Czech biotech” exist…? • “hype” world • overused “buzzwords” or “cliché” – “open science” • share all with everyone vs. share all with everyone after you protect your IP
– “there is no industry to collaborate with and/or sell the results to” • local vs. global à is the “science” global...? 10
comments and recommendations • be carefully open – secure your IP first!
• internationalize – attract people AND money worldwide
• try to think out-of-the-box – look for partners even outside (your field, country …) 11
Thank you for your attention.
Web: www.tacr.cz Facebook: http://www.facebook.com/tacr.cz LinkedIN: http://www.linkedin.com/company/technologick-agentura-esk-republiky Twitter TA CR: http://twitter.com/TACR_cz YouTube: https://www.youtube.com/channel/UC1arGrQjwIKbQGDrpIB-n0A Google+: http://plus.google.com/u/0/b/105572200316564197586/105572200316564197586/posts
